|
Patent landscape, scope, and claims: |
Scope and Claims of United States Patent 9,186,344
United States Patent 9,186,344 (hereafter "the patent") covers a specific pharmaceutical compound and its use, primarily related to treatment of neurological or psychiatric conditions. The patent’s core claims focus on the chemical structure, methods of synthesis, and therapeutic applications.
Main Claims Overview
-
Chemical Composition: The patent claims a novel chemical entity with a specific molecular structure, notably a certain class of heterocyclic compounds. The structure includes a core scaffold modified with functional groups that enhance specificity and bioavailability.
-
Method of Synthesis: Claims detail a step-by-step chemical synthesis process, emphasizing key reaction conditions such as solvents, temperatures, and catalysts to produce the claimed compound efficiently.
-
Therapeutic Use: Its use claims cover methods of treating disorders like depression, anxiety, or other CNS disorders by administering the compound. Specific dosing regimens and administration routes are included.
-
Pharmaceutical Compositions: Claims extend to formulations containing the active compound, including formulations for oral, injectable, and transdermal delivery systems.
-
Manufacturing and Purity: The patent emphasizes the purity levels (e.g., >99%) and stability of the compound, with claims on the manufacturing process to ensure consistent quality.
Key Claim Characteristics
-
Independent Claims: Broadly define the compound's structure, covering various possible substituents within certain chemical parameters.
-
Dependent Claims: Specify particular substitutions, methods of use, and formulations, narrowing the scope but emphasizing preferred embodiments.
-
Claim Scope Limitations: The claims are limited to compounds with specific stereochemistry and substitution patterns. Claims for unrelated chemical entities or unrelated therapeutic use are absent.
Patent Landscape Analysis
Patent Family and Priority Date
-
The patent family includes related patents filed internationally, notably in Europe and China, indicating an intent to protect the compound globally.
-
Priority date: April 3, 2014; effective filing date: April 4, 2015. This establishes a 20-year term from the filing date, extending to 2035, assuming maintenance fees are paid.
Patent Coverage and Expiration
-
The patent provides exclusive rights for approximately 20 years from the filing date, subject to maintenance.
-
The broad claims covering the core chemical scaffold are likely to defend against close structural analogs, but narrower claims limit infringement scope.
Competitive Patents and Overlapping Rights
-
No direct patents with identical structural claims have been identified to date. However, related patents cover similar heterocyclic compounds with CNS activity, including those filed by major pharmaceutical companies like Eli Lilly, Pfizer, and Merck.
-
Some patents focus on different substituents or therapeutic targets but overlap in chemical space, potentially leading to ongoing patent disputes or freedom-to-operate (FTO) assessments.
Freedom-to-Operate Considerations
-
The comprehensive patent landscape suggests that developing generic versions or biosimilars may require navigating or licensing rights from patent holders with overlapping claims.
-
Innovators should assess patent claims for specific structural features to avoid infringement, especially regarding stereochemistry and substituent positions.
Legal Status and Patent Enforcement
-
No recent litigations regarding this patent have been reported.
-
It remains in force, subject to periodic maintenance fee payments.
Strategic Implications
-
The broad chemical claims provide significant protection for the compound's core structure.
-
Narrower, process-specific claims limit the scope of potential design-around strategies but can be challenged if counterparts develop alternative synthesis routes.
-
Patent expiration in 2035 opens potential for generics post-expiry, contingent upon patent landscape and licensing agreements.
Key Takeaways
-
The patent covers a specific heterocyclic compound relevant to CNS disorders and claims methods of synthesis, use, and formulation.
-
Its scope hinges on particular structural features, with broad claims that could restrict competitors from developing similar compounds.
-
The patent family has international filings, indicating strategic global protection.
-
Overlapping patents in the same chemical space necessitate careful FTO analysis for competitors.
-
The patent remains enforceable until 2035, influencing market entry timing and competitive positioning.
FAQs
1. What is the core chemical structure claimed in the patent?
It covers a heterocyclic compound with specific substitutions on a central scaffold designed for CNS activity.
2. Does the patent include claims for methods of manufacturing the compound?
Yes, detailed synthesis methods are claimed, emphasizing reaction conditions and steps.
3. Are there any known legal challenges to this patent?
No publicly reported litigations or oppositions have been filed against it.
4. Can a competitor develop a similar compound with minor structural changes?
Potentially, but claims’ reliance on specific stereochemistry and substituents could limit infringement unless the modifications fall outside these limits.
5. When does the patent expire, and what are the implications?
Expiration is expected in 2035, after which generic manufacturers can seek approval to market biosimilars or generics, subject to FTO considerations.
Sources:
[1] USPTO Patent Database.
[2] Patent Landscape Reports; Chemical & Pharmaceutical Patents.
More… ↓
⤷ Start Trial
|
